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Abstract 
A hybrid molecule generated by fusing the regulatory domain of PKCd with the catalytic domain of PKC-c is, like PKCd but unlike PKC-6, 
a phorbol ester-dependent enzyme. However, the substrate specificity of this hybrid resembles that of PKC-C. Expression of mammalian PKC-8, 
but not PKC-C, in the fission yeast Schizosucchnromycespombe causes growth retardation and phorbol esters amplify the PKC-S phenotype without 
affecting that of PKC-I: (Goode et al., submitted). The chimaeric molecule also inhibited growth and this effect was phorbol-ester dependent. Both 
the hybrid and PKC-6 holoenzyme, in contrast o PKC-C, down-regulate upon prolonged exposure to phorbol esters in vivo. Thus, this hybrid retains 
the regulatory properties conferred by PKC-6 but the catalytic properties of PKC-C. This regulatable chimaeric molecule will be useful in assessing 
the function of PKC-6. 
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1. Introduction 
Mammalian protein kinase C (PKC) consists of a fam- 
ily of at least ten polypeptides encoded by nine genes 
[ 1,2]. Within the family, three distinct groups have been 
identified based on both structural and functional crite- 
ria [Z]. PKC-ol, -&, -j$,, and -y, which were the first to 
be cloned, have been termed classical PKCs (cPKC); 
PKC-6, -E, -77 and -0 are novel PKCs (nPKC) and PKC-6 
and -ZJ. are atypical (aPKC). In general, the PKC mole- 
cule is divided into four constant regions (C,-C,) sepa- 
rated by five variable regions (V,-V,). Functionally the 
enzyme consists of the amino terminal regulatory do- 
main, which contains the C, and C, regions, and the 
carboxy terminal catalytic domain, containing the C3 
and C4 regions. The hinge region V, connects these func- 
tional domains. The C, region contains a sequence with 
homology to a consensus PKC substrate site but lacking 
a phosphate accepting serine or threonine (see El]). This 
sequence, known as the pseudosubstrate site (PSS), has 
been proposed to function in maintaining the enzyme in 
an inactive state through a non productive association 
with the catalytic domain (discussed in [5,6]). The C, 
region of the cPKCs and nPKCs also contains two cys- 
teine-rich sequences that have been shown to be the site 
of interaction with the phospholipid and diglyceride/ 
phorbol ester activators [3,4]. However, the aPKC se- 
quences contain only one cysteine-rich region in C, and 
it has been established that PKC-c differs from the other 
PKCs in dependency on lipid activators, especially phor- 
bol esters, both in vitro [7-91 and in vivo [IO,1 11. 
The distinct lipid dependence of PKC-< and our conse- 
quent lack of understanding of its regulation has limited 
our appreciation of its functional significance in viva, An 
approach to this issue has developed from our previous 
work on chimaeric PKC mutants which retain their reg- 
ulatory properties [12]. Here we demonstrate that a 
chimaeric PKC-616 molecule retains J-dependent phor- 
bol ester regulation in vitro whilst the substrate specific- 
ity of this mutant, as specified by the PKC-c kinase 
domain, is conserved. In vivo this chimera, in contrast 
to PKC-6, is responsive to phorbol esters and induces a 
growth phenotype upon expression in Sc~izo~acc~aro- 
myces pombe. 
2. Experimental 
2. I. Cell strain and culture 
*Corresponding author. Fax: (44) (71) 269 3092. 
Abbreviations: PKC, protein kinase C; PSS, pseudosubstrate site; TPA, 
12-O-tetradecanoylphorbol 13-acetate; PS, phosphatidylserine. 
The yeast strain Ade6.704, Leul-32, Urad4, h- was routinely cultured 
at 32°C in rich YE medium or in synthetic Edinburgh minimal medium 
supplemented with 2% (w/v) glucose, 100 &ml adenine and leucine, 
and free of uracil (minimal selective medium) to select for the stable 
propagation of the expression plasmids [13]. Transformation was by 
electroporation using the manufacturer’s instructions (Bio-Rad Pulse 
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Controller) and the transformants were spread onto minimal selective 
plates containing 1 M sorbitol and 1 ,uM thiamine. Individual colonies 
were plated onto minimal selective plates with no additives or contain- 
ing 100 ng/ml 12-O-tetradecanoylphorbol 13-acetate (TPA) or 1 PM 
thiamine to assay for a growth phenotype. Cultures were routinely 
started by picking a colony into minimal selective medium containing 
thiamine and culturing overnight until mid-log phase. Cells were then 
washed to remove thiamine, rediluted into fresh minimal selective me- 
dium with the appropriate additives (thiamine or TPA) and cultured for 
a further 2448 h as described in the text. Growth status was assessed 
by measuring the OD,,, (0.4 units = 10’ cells/ml). 
2.2. Expression plasmids 
The pREP4 expression plasmid is a derivative of PREP1 [14] except 
that the NdeI site in the multiple cloning site has been replaced by a Bali 
site and the selectable marker is the URA4 gene. Expression in this 
plasmid is driven by the nmtl promoter which expresses at I-fold the 
level of the ADH promoter and is repressed IO-fold by thiamine [14,1.5]. 
All subcloning methods used were as described [16]. The cDNA for 
PKCd was excised from the pREP3X-PKC-6 plasmid (Goode et al., 
submitted) as an SphI-BamHI fragment and ligated into pREP4 di- 
gested with the same enzymes. The PKC-C cDNA was excised as an 
XbaI fragment from pBluescript-PKC-6 [11] and, after filling the re- 
cessed ends with the Klenow fragment of DNA polymerase I, was 
subcloned into a Ba&SmaI digested vector. The PKC-cAl19E substi- 
tution was made using PCR (D.K. Ways and P.J.P., unpublished) 
essentially as described for other mutations [17,18] and was subcloned 
from pBluescript into pREP4 using an identical strategy as for PKC-C. 
This substitution, in the PSS of PKC-5, is equivalent o the A25E and 
Al6lE substitutions of PKC-a [17] and PKCg [19], respectively. Both 
of these mutant molecules are constitutively active being co-factor inde- 
pendent for activity [17,19]. To construct he chimaeric molecule, the 
2.2-kb SphI-ScaI fragment (containing the promoter of the vector and 
the aminoterminal sequence of PKCL6 LIP to and including the V3 
region) was isolated from oREP3X-PKC-6 and subcloned into oREP4- 
PI&-i which had been djgested with ClaI, blunt ended with i(lenow 
and then digested with SphI (which contained the V,, C3, V,, C4 and 
V, domains of PKC-6 but lacked V,, C,, V, and C,). 
2.3. Protein extracts and PKC assays 
Denatured protein extracts were made from equivalent numbers of 
cells by standard techniques [13] and SDS-PAGE and western blotting 
were performed as previously [20]. Polyclonal rabbit isotype-specific 
PKCd and -c antibodies directed against he carboxy termini (see [20] 
and references therein), and a polyclonal antiserum against the V3 
region of PKCd (A.R. Olivier, S. Kiley and P.J.P., unpublished) were 
followed by donkey anti rabbit horse radish peroxidase-conjugated 
antibodies and the ECL detection system (Amersham International). 
Native proteins for PKC activity analysis were extracted from mid 
log phase cell strains cultured in the absence of thiamine for 30 h 
essentially as described [13] except hat the extraction buffer contained 
20 mM Tris pH 8.0, 5 mM EDTA, 5 mM EGTA, 0.3% (v/v)B-mercap- 
toethanol, 0.5% (v/v) Triton X-100, 10 mM benzamidine, 50 &ml 
PMSF, 50 pg/ml ovalbumin and 100 &ml leupeptin. After clearing by 
centrifugation, the extracts were loaded onto a 1 ml HiTrap Heparin 
column (Pharmacia) using an FPLC. After washing with 5 column 
volumes of buffer (20 mM Tris pH 8.0, 2 mM EDTA, 5 mM EGTA, 
0.3% (v/v) /?-mercaptoethanol, 0.1% (v/v) Triton X-100 and 10 mM 
benzamidine), proteins were eluted with a linear O-1.5 M NaCl gradient 
(15 x 0.5 ml 1 min fractions). 5 ~1 of column fractions were assayed 
using 250 &ml of the serine containing GPSS peptide as substrate in 
the presence or absence of phosphatidylserine (PS, 1.25 mg/ml) and 
TPA (250 @ml) as described previously [21]. Protein concentrations 
were measured by Bradford assay (Bio-Rad) and used to correct for 
variation in extraction and recovery. 
Peak activity fractions of the PKC-B and -S/cprofiles were compared 
with respective vector control fractions for kinase activity (in the pres- 
ence of PS/TPA) against a titration of the a, 6 and @SS peptides, 
centred around Km values expected from previous work [21]. From 
preliminary experiments, it was known that PKC-[ eluted between 
1. l-l .4 M NaCI. Fraction 12 of the PKC-[ and -CA1 19E profiles were 
also compared with vector controls for kinase activity (inthe presence 
or absence of PS and TPA) using 250 pg/ml (178 PM) GPSS, 500 peg/ml 
(255 PM) aPSS or 375 pg/ml(259,~M) @SS peptides as substrates (see 
[21] and references therein). 
3. Results and discussion 
Given the lack of response of PKC-c to the classic 
PKC activator, TPA [7,10,11], and our inability to acti- 
vate this isotype by other means in a whole cell context, 
we were interested to develop a regulatable form of PKC- 
c. The protein kinase specificity of PKCs, and therefore 
function, is determined in part by the catalytic domain 
of the enzyme. Therefore a chimaeric molecule was cre- 
ated, replacing the regulatory domain of PKC-c with 
that of PKC-6, in the hope that an enzyme with the 
output of PKC-c but regulated in a PKC-6 fashion 
would result. S. pombe was chosen as an expression 
vehicle because the low background of TPA-dependent 
kinase activity (Goode et al., submitted) assists in inter- 
pretation when compared with mammalian cells which 
generally express several PKC isotypes (e.g. [20,22]). 
Mammalian PKC-6, -C, the PKC-G/c chimera and a 
constitutive PKC-c mutant, PKCJA119E, were sub- 
cloned into the pREP4 vector which uses the powerful 
but thiamine repressible nmtl promoter to drive expres- 
sion [ 141. These plasmids were transformed into S. pombe 
cells by electroporation, and individual transformants 
were picked into 1 ml of minimal selective liquid medium 
in the absence of thiamine. Denatured extracts, collected 
after 30 h of culture, were analysed for expression of the 
relevant mammalian PKC by western blotting using 
isotype-specific PKC antisera (data not shown). 
3.1. Regulation and substrate range of expressed proteins 
Representative colonies expressing PKC-6, -[, -S/c or 
-CA1 19E and vector control were expanded in liquid 
culture (in the absence of thiamine). Triton X-100 solu- 
ble proteins extracted from 100 ml of these cultures were 
loaded onto a 1 ml HiTrap Heparin column and eluted 
with a O-l.5 M NaCl gradient. Fractions were assayed 
for activity dependent on the PKC co-factors PS and 
TPA using the SASS peptide as substrate. Fractions were 
also analysed by SDS-PAGE and Western blotting using 
the carboxy terminal PKC-J or -c specific antisera. Col- 
umn profiles with relevant western blots are shown in 
Fig. 1. PKC-6 elutes at 0.7-0.9 M NaCl which accounts 
for the main peak of co-factor dependent activity, with 
the catalytic domain fragment eluting at 0.7 M and gen- 
erating the co-factor independent activity. The main 
peak of the chimaeric protein elutes at 0.9-l. 1 M NaCl 
correlating with the activity peak. Catalytic domain frag- 
ments elute at 0.8-0.9 M but the associated activity is 
relatively low compared with that of the full length en- 
zyme. PKC-[ and -CA1 19E elute with the peak protein 
at 1.2-1.3 M NaCl but no kinase activity is associated 
with these proteins when using the GPSS substrate. Cata- 
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Fig. 1. Activity profiles of column fractions using the GPSS substrate. 5 ~1 of column fractions of extracts from vector control, PKC-6, -c, -85 and 
-[Al 19E cells were assayed for co-factor dependent activity (open symbols, - PS/TpA, filled symbols, + PS/TPA) using the GPSS as substrate. After 
subtraction of background counts and correction for protein concentration, results are plotted as net activity (vector control activity has been 
subtracted). Each fraction represents a 0.1 M increase in NaCl concentration (fraction 0 = 0 M). Figures are means of duplicate samples. Aliquots 
of the same fractions were denatured and analysed by SDS-PAGE and western blotting. The positions of the full length proteins and catalytic domain 
fragments are indicated by filled and open arrowheads, respectively. 
lytic domain fragments for both of these enzymes elute tion of substrate specificity, and the kinase domain of 
at 0.7-0.9 M NaCl and may account for the small peaks PKC6 and the hybrid are different, the ability of the 
of activity in these fractions. Thus these four enzymes PKC-6/c chimera and of PKC-8 to phosphorylate a 
can be separated by a single liquid chromatography step. panel of pseudosubstrate site peptides was assessed. Peak 
The PKC-6 regulatory domain renders the PKC-C cata- fractions of PKC-6 (fraction 8) and of PKC-G/c (fraction 
lytic domain co-factor dependent for activity. 10) were compared with the same fractions from vector 
Since the kinase domain contributes to the determina- control chromatograms. The amount of PKC in the rel- 
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evant fractions was equilibrated by densitometer scan- 
ning of western blots probed with a polyclonal antiserum 
directed against he V3 region of PKC-S, which is present 
in both of these molecules (data not shown). The results 
(net values after correction for protein concentration and 
subtraction of the appropriate vector control values) are 
shown in Fig. 2. PKC-6 exhibits a higher apparent affin- 
ity for all three peptides than does the chimera. PKC-6 
shows a preference for both the @SS and GPSS peptides 
over the aPSS peptide (apparent K, values for these 
peptides were 1.3, 2.9 and 28 PM, respectively). The 
apparent K, values for these peptides of PKC-G/l al- 
though weaker follow a similar pattern but with clear 
preference for the @SS (K,,, values for the 6,6 and aPSS 
peptides were 4.3, 18 and 80 ,uM, respectively). The 
PKC-G/c hybrid exhibits higher V,,, values for the aPSS 
and SpSS peptides than for GPSS (values of 0.65, 0.38 
and 0.17 pmol/min/pg protein) which is the opposite to 
the activity pattern of PKC-S (values of 0.23, 0.27 and 
0.34 pmol/min@g for the same peptides). The K,,, values 
(V,,/K,,J show that there is a clear divergence in speci- 
ficity with respect o the SASS, with relative K,,, values 
of 1:0.6:0.05 for PKC6 on the c, 6 and a peptides, 
respectively, while PKC-G/c shows ratios of 1:O.ll:O.l 1 
in the same analysis. 
The S/c hybrid demonstrates higher V,,, values for the 
a and @SS peptides than for the GPSS peptide. This 
pattern may reflect the substrate preference of the PKC-l 
kinase domain and could partially explain the lack of 
detection of PKC-[ and -CA1 19E kinase activity when 
using the GPSS as substrate (Fig. 1). To establish the 
substrate preference of PKC-C, we determined the ability 
of the PKC-% holoenzyme and the constitutive mutant to 
phosphorylate the same panel of PSS peptides.. Peak 
fraction 12 of PKC-C and -CA1 19E eluants, which con- 
tain similar amounts of these PKC-% enzymes (Fig. l), 
were compared with the same fraction from the vector 
controls. Neither of these enzymes phosphorylated the 
GPSS (Fig. 3 and above). However, the constitutive 
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PKC-C mutant, and to a lesser extent the holoenzyme, 
phosphorylated the SpSS peptide; the aPSS peptide is 
also a substrate if somewhat poorer (Fig. 3). The PKC-c 
holoenzyme appears to be a poor kinase. However, these 
assays have been optimised for the activation of PKC6 
and not PKC-c. It is therefore not surprising that the c 
holoenzyme is not active in these assays. Indeed, the 
activity associated with the PKC-LJ mutant is constitu- 
tive, showing no difference in the presence or absence of 
activators (data not shown). In the absence of activation 
of the holoenzyme, the constitutive mutant can be con- 
sidered as representing the intrinsic peptide preference of 
PKC-c. Thus PKC-C exhibits distinct peptide substrate 
preferences. PKC-SA119E is expressed at approximately 
24 f 16% of the level of the S/c chimera (as determined 
by densitometer tracing of western blots from 4 experi- 
ments). If this lower level of expression of PKC-cA119E 
is considered, the observed pattern of peptide phospho- 
rylation and the lack of perceived SASS phosphorylation 
are consistent quantitatively with the activity of the S/c 
chimera. 
We have shown that the hybrid molecule is active in 
vitro and has a substrate preference resembling that of 
PKC-[, but appears to be regulated like PKC-S (it can 
be purified as a phorbol ester dependent kinase). To 
confirm the TPA-dependence of PKC-6/c, a titration 
with TPA was carried out and comparison made with 
PKC-6. Both show TPA-dependence over the range 0.2- 
25 ng/ml with PKC-8 appearing more sensitive (data not 
shown). 
3.2. Growth effects in S. pombe 
These studies were initiated to obtain a regulatable 
form of PKC-c which could be used in whole cell sys- 
tems. Since the molecules are expressed in S. pombe on 
a tightly repressible promoter, the consequence of ex- 
pression can be assessed. We have shown previously that 
mammalian PKC-8 produces a growth inhibition- in S. 
pombe which is enhanced by phorbol esters whereas 
- OILi y 1 , , , ‘j , !_]I 
0 2.50 500 750 loo0 0 so 100 I.50 200 0 loo 200 300 ‘wo 500 
yM aPSS peptide FM SPSS peptide ,uM ZJ’SS peptide 
Fig. 2. PKC-S/c and PKC-8 have distinct substrate specificities. Fraction 8 of PKC8 (0) and fraction 10 of PKCWC (A) were assayed in the presence 
of PSiTPA using titrations of the serine containing aPSS, GPSS and PSS peptides as substrates. After correction for protein concentration, the 
appropriate vector control values were subtracted. The amount of PKC in the respective fractions was compared by western blotting followed by 
densitometer scanning and the values were corrected for relative PKC concentration. Values for apparent K,,, and V,,,,,, calculated on the basis of 
inverse plots of substrate concentration and activity, are included in the text. 
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Fig. 3. PKC-cAl19E and PKC-C specificity towards PSS peptides. 
Fraction 12 from vector control, PKC-C and PKC-cA119E cells (as 
indicated) were assayed using the GPSS, @SS and aPSS peptides as 
substrates, as described in section 2. Data shown, from assays per- 
formed in the presence of PSITPA, was not significantly different from 
co-factor independent values. Results are means and ranges of dupli- 
cate samples. 
PKC-C has no detectable ffect (Goode et al., submitted). 
Representative colonies of vector controls or transfor- 
mants expressing PKC-6, -c, -S/c or -SA119E were 
spread onto minimal selective solid media with or with- 
out 1 PM thiamine. PKC6 expression produces a signif- 
icant reduction in colony size and the chimaeric molecule 
repeatably produced a slight growth inhibition (Fig. 4, 
compare plates A and B). Expression of PKC-5 and 
-CA1 19E produced no growth effect (Fig. 4, plates A and 
B and data not shown). 
PKC-S is activated by phorbol esters both in vitro and 
in vivo [20,21,23] and we have shown that the chimaeric 
molecule is activated by TPA in vitro. To ascertain if the 
chimera was also activated by TPA in vivo, the effect of 
TPA treatment on the transformed S. pombe strains was 
determined. Cells were streaked onto minimal selective 
plates which contained 100 &ml TPA (Fig. 4, plate C 
and data not shown). The colony size of vector controls 
Fig. 4. Growth effects of PKC-8, -c and -S/r and response to TPA. 
Colonies transformed with pREP4, pREP4-PKC-6, -5 or -S/c were 
plated onto minimal selective medium with 1 PM thiamine (A), no 
additive (B) or 100 @ml TPA (C) and incubated at 32°C for 3 days. 
and PKC-6 and -6A119E was not affected by TPA 
whereas the yeast strain expressing the chimaeric mole- 
cule was further growth inhibited and PKCB transfor- 
mants ceased growth (some large colonies seen with 
PKC6 plated on TPA reflect loss of functional PKC-S 
since the vast majority of colonies are seen as a feint 
lawn). Therefore, the chimaeric molecule produces a 
phenotype in S. pombe and is responsive to TPA. A form 
of PKC-C (PKC- CA1 19E) which is constitutively active, 
and has the same substrate specificity as the S/c chimera, 
produces no growth effects in this biological assay. This 
apparent inconsistency can be explained by the lower 
levels of expression of PKC-cA119E compared with 
PKC-6/c. 
A characteristic of sustained TPA treatment is the 
down-regulation of most PKC isotypes and this phenom- 
enon has been linked to the ability to activate the rele- 
vant PKC. For example, PKC-6 does not down-regulate 
and is not activated by TPA [ 10,l l] whereas PKC-6 both 
down-regulates and is activated [20,23]. To determine if 
the hybrid molecule behaves like PKC-6 in vivo, its re- 
sponse to TPA in S. pombe was analysed. Extracts taken 
from cells grown in liquid culture for 30 h in the presence 
or absence of TPA (without thiamine) were examined by 
western blotting. TPA causes the down-regulation of 
PKC-6 and the levels of PKC-6/c protein are reduced by 
approximately 80% whereas PKC-c does not down-regu- 
late (Fig. 5). The PKC-8 regulatory domain therefore 
confers TPA sensitivity to the chimaeric molecule in this 
biological context. An implication of this finding is that 
the kinase specificity of PKC-%, as defined by that of the 
chimera, is appropriate for triggering the process of 
down-regulation. This phenomenon has an active char- 
TPA - + - + - + - + - + 
Fig. 5. TPA causes the down-regulation of PKC-B and -S/c but not 
PKC-C. Extracts from vector controls (-) and cells expressing PKCd, 
PKC-C or PKC-6/c cultured in the presence or absence of TPA (+I-) 
for 30 h (in absence of thiamine) were analysed by SDS-PAGE and 
Western blotting using isotype-specific anti-PKC-6 (lanes 14) or PKC- 
c(lanes 5-10) antibodies. Arrows indicate molecular mass (kDa). PKC- 
6 and -c migrate at 7680 kDa whereas the chimaeric molecule has an 
increased molecular mass of approximately 87 kDa due to duplication 
of the V, region during construction. 
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acteristic (NTG and PJP, manuscript in preparation) 
that is fulfilled by PKC-G/c. 
Thus PKC-6 expression in S. pombe produces a 
growth inhibition which can be amplified by phorbol 
ester treatment whereas PKC-[ expression has no effect 
on growth. A hybrid molecule which contains the regula- 
tory domain of PKC6 and the catalytic domain of PKC- 
c behaves like PKCB in this assay although the growth 
effects are less marked. The PKC-S regulatory domain 
renders the chimaeric molecule TPA sensitive for both 
phenotypic effects and down-regulation. 
In conclusion, a chimaeric molecule has been con- 
structed which retains the characteristics of its constitu- 
ent halves. A PKC has been generated which has the 
substrate specificity of PKC-[ but can be regulated both 
in vitro and in vivo by phorbol esters, in contrast to the 
PKC4’holoenzyme. Since there are no proven activators 
for PKC-5 which can be used in a whole cell context, this 
molecule should greatly assist in the elucidation of the 
function of PKC-5. 
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